798 Impact of third line ZD 1839 therapy on patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme)

✍ Scribed by F. De Marinis; A. Mancuso; O. Martelli; M.R. Migliorino; R. Di Salvia

• Book ID: 118620964
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 159 KB
• Volume: 1
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(03)90823-8